Journal article
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Abstract
BACKGROUND: Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile.
OBJECTIVE: To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with …
Authors
Puig L; Augustin M; Blauvelt A; Gottlieb AB; Vender R; Korman NJ; Thaçi D; Zhao Y; Gilloteau I; Sherif B
Journal
Journal of the American Academy of Dermatology, Vol. 78, No. 4, pp. 741–748
Publisher
Elsevier
Publication Date
April 2018
DOI
10.1016/j.jaad.2017.10.025
ISSN
0190-9622